Background: Primary intracranial germ cell tumour is a rare entity and constitutes 2-3% of all paediatric brain tumours in Western countries. We herein intend to report the clinical features and treatment outcome of patients with primary central nervous system germ cell tumour treated at our institute. Methods: Clinical data were collected by retrospective chart review from 2006 to 2012. Histopathology slides were reviewed and relevant immunohistochemistry stains were done. Overall survival (OS) and progression-free survival (PFS) were analysed by the Kaplan-Meier product-limit method. Results: Twenty patients met the study criterion (male:female = 7:3). Median age at presentation was 13 years. Tumour location was pineal in 10 patients, suprasellar in 6, thalamic in 2, basal ganglion in 1, and spinal in 1. Leptomeningeal spread was noted in 1 patient at presentation. Surgical resection was gross-total in 7 patients (35%), near-total in 2 (10%), subtotal in 4 (20%), and limited to biopsy in 6 (30%). The tumours were germinomatous, non-germinomatous, and of mixed germ cell subtype in 17 patients (85%), 2 patients (10%), and 1 patient (5%), respectively. Systemic chemotherapy (median of 4 cycles) was given to 19 patients (95%). The common regimens used were a combination of bleomycin, etoposide and cisplatin (BEP) in 14 patients (70%) and etoposide and cisplatin (EP) in 5 patients (25%). Radiation therapy (40-50 Gy in conventional fractionation; median of 42 Gy) was delivered to 17 patients (85%): local radiation in 6 and whole ventricular, whole brain, and craniospinal irradiation followed by a boost in 5, 3, and 3 patients, respectively. After a median follow-up of 44.52 months, 17 patients (85%) were in complete response and 3 (15%) had progressive disease. Death and disease recurrence were noted in 6 patients (30%) and 1 patient, respectively. Median OS and PFS were not reached. The actuarial rates of OS at 3 and 5 years were 75.8 and 68.9%, respectively. The actuarial rates of PFS at both 3 and 5 years were 81.6%. Conclusion: Multimodality treatment consisting of limited resection followed by platinum-based systemic chemotherapy and radiotherapy (40-50 Gy) is a reasonable treatment strategy in patients of primary central nervous system germ cell tumour in a developing nation.

Keywords:
Cisplatin, Craniospinal irradiation, Germ cell tumour, Intracranial tumours, Radiotherapy
1.
Echevarría ME, Fangusaro J, Goldman S: Pediatric central nervous system germ cell tumors: a review. Oncologist 2008;13:690-699.
2.
Mufti ST, Jamal A: Primary intracranial germ cell tumors. Asian J Neurosurg 2012;7:197-202.
3.
Huo L, Wang X, Allen PK, Wang L, Liao Y, Han Z, Shen L, Tu Q, Zhong M, Zhuang Y, Li J, Hong J: Predictors of long-term survival following postoperative radiochemotherapy for pathologically confirmed suprasellar germ cell tumors. Mol Clin Oncol 2015;3:430-434.
4.
Balmaceda C, Finlay J: Current advances in the diagnosis and management of intracranial germ cell tumors. Curr Neurol Neurosci Rep 2004;4:253-262.
5.
Fujimaki T: Diagnostic imaging of intracranial germ cell tumors: a review; in Matin A (ed): Germ Cell Tumor, ed 1. Shanghai, Tech, 2012, pp 47-58.
6.
Murray MJ, Bartels U, Nishikawa R, Fangusaro J, Matsutani M, Nicholson JC: Consensus on the management of intracranial germ-cell tumours. Lancet Oncol 2015;16:e470-e477.
7.
Macdonald D, Cascino T, Schold SJ, Cairncross J: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-1280.
8.
Makino K, Nakamura H, Yano S, Kuratsu J; Kumamoto Brain Tumor Group: Population-based epidemiological study of primary intracranial tumors in childhood. Childs Nerv Syst 2010;26:1029-1034.
9.
Lin IJ, Shu SG, Chu HY, Chi CS: Primary intracranial germ-cell tumor in children. Zhonghua Yi Xue Za Zhi (Taipei) 1997;60:259-264.
10.
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P: The 2007 WHO Classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97-109.
11.
Freeman CR, Farmer JP, Taylor RE: Central nervous system tumors in children; in Halperin EC, Wazer DE, Perez CA, Brady LW (eds): Perez and Brady's Principles and Practice of Radiation Oncology, ed 6. Philadelphia, Lippincott Williams & Wilkins, 2013, pp 1632-1655.
12.
Jaing TH, Wang HS, Hung IJ, Tseng CK, Yang CP, Hung PC, Lui TN: Intracranial germ cell tumors: a retrospective study of 44 children. Pediatr Neurol 2002;26:369-373.
13.
Matsutani M, Sano K, Takakura K, Fujimaki T, Nakamura O, Funata N, Seto T: Primary intracranial germ cell tumors: a clinical analysis of 153 histologically verified cases. J Neurosurg 1997;86:446-455.
14.
Sawamura Y, Ikeda J, Shirato H, Tada M, Abe H: Germ cell tumors of the central nervous system: treatment considerations bases on 111 cases and their long-term clinical outcome. Eur J Cancer 1998;34:104-110.
15.
Sawamura Y, de Tribolet N, Ishii N, Abe H: Management of primary intracranial germinomas: diagnostic surgery or radical resection? J Neurosurg 1997;87:262-266.
16.
Nam DH, Cho BK, Shin HJ, Ahn HS, Kim IH, Wang KC: Treatment of intracranial nongerminomatous malignant germ cell tumor in children: the role of each treatment modality. Childs Nerv Syst 1999;15:185-191.
17.
Balmaceda C, Heller G, Rosenblum R, Diez B, Villablanca JG, Kellie S, Maher P, Vlamis V, Walker RW, Leibel S, Finlay JL: Chemotherapy without irradiation - a novel approach for newly diagnosed central nervous system germ cell tumors: results of an international cooperative trial. J Clin Oncol 1996;14:2908-2915.
18.
Schild SE, Haddock MG, Scheithauer BW, Marks LB, Norman MG, Burger PC, Wong WW, Lyons MK, Schomberg PJ: Non germinomatous germ cell tumors of the brain. Int J Radiat Oncol Biol Phys 1996;36:557-563.
19.
Huh SJ, Shin KH, Kim IH, Ahn YC, Ha SW, Park CI: Radiotherapy of intracranial germinomas. Radiother Oncol 1996;38:19-23.
20.
Rogers SJ, Mosleh-Shirazi MA, Saran FH: Radiotherapy of localised intracranial germinoma: time to sever historical ties? Lancet Oncol 2005;6:509-519.
21.
Calaminus G, Kortmann R, Worch J, Nicholson JC, Alapetite C, Garrè ML, Patte C, Ricardi U, Saran F, Frappaz D: SIOP CNS GCT 96: final report of outcome of a prospective, multinational nonrandomized trial for children and adults with intracranial germinoma, comparing craniospinal irradiation alone with chemotherapy followed by focal primary site irradiation for patients with localized disease. Neuro Oncol 2013;15:788-796.
22.
Baranzelli MC, Patte C, Bouffet E: Carboplatin-based chemotherapy (CT) and focal radiation (RT) in primary cerebral germ cell tumors (GCT): A French Society of Pediatric Oncology (SFOP) experience. Proc Am Soc Clin Oncol 1999;18:140A.
23.
Calaminus G, Frappaz D, Kortmann R, Alapetite C, Garre ML, Ricardi U, Saran FH, Nicholson J: GC-11: risk adapted irradiation is feasible in intracranial non-germinomatous germ cell tumours (NGGCT): final results of SIOP CNS GCT 96. Neuro Oncol 2012;14 (suppl 1):i51.
24.
Shirato H, Nishio M, Sawamura Y, Myohjin M, Kitahara T, Nishioka T, Mizutani Y, Abe H, Miyasaka K: Analysis of long-term treatment of intracranial germinoma. Int J Radiat Oncol Biol Phys 1997;37:511-515.
25.
Sakanaka K, Mizowaki T, Hiraoka M: Dosimetric advantage of intensity-modulated radiotherapy for whole ventricles in the treatment of localized intracranial germinoma. Int J Radiat Oncol Biol Phys 2012;82:e273-e280.
26.
Bouffet E, Baranzelli MC, Patte C, Portas M, Edan C, Chastagner P, Mechinaud-Lacroix F, Kalifa C: Combined treatment modality for intracranial germinomas: results of a multicentre SFOP experience. Société Française d'Oncologie Pédiatrique. Br J Cancer 1999;79:1199-1204.
27.
Douglas JG, Rockhill JK, Olson JM, Ellenbogen RG, Geyer JR: Cisplatin-based chemotherapy followed by focal, reduced-dose irradiation for pediatric primary central nervous system germinomas. J Pediatr Hematol Oncol 2006;28:36-39.
28.
Robertson PL, DaRosso RC, Allen JC: Improved prognosis of intracranial non-germinoma germ cell tumors with multimodality therapy. J Neurooncol 1997;32:71-80.
29.
Calaminus G, Bamberg M, Harms D, Jürgens H, Kortmann RD, Sörensen N, Wiestler OD, Göbel U: AFP/beta-HCG secreting CNS germ cell tumors: Long-term outcome with respect to initial symptoms and primary tumor resection. Results of the cooperative trial MAKEI 89. Neuropediatrics 2005;36:71-77.
30.
Calaminus G, Bamberg M, Jo¨rgens H, Kortmann RD, Sörensen N, Wiestler OD, Göbel U: Impact of surgery, chemotherapy and irradiation on long term outcome of intracranial malignant nongerminomatous germ cell tumors: results of the German Cooperative Trial MAKEI 89. Klin Padiatr 2004;216:141-149.
31.
Matsutani M; Japanese Pediatric Brain Tumor Study Group: Combined chemotherapy and radiation therapy for CNS germ cell tumors - the Japanese experience. J Neurooncol 2001;54:311-316.
32.
Ogawa K, Toita T, Nakamura K, Uno T, Onishi H, Itami J, Shikama N, Saeki N, Yoshii Y, Murayama S: Treatment and prognosis of patients with intracranial nongerminomatous malignant germ cell tumors: a multiinstitutional retrospective analysis of 41 patients. Cancer 2003;98:369-376.
33.
Jennings MT, Gelman R, Hochberg F: Intracranial germ-cell tumors: natural history and pathogenesis. J Neurosurg 1985;63:155-167.
34.
Finlay JL: The role of high dose chemotherapy and stem cell rescue in the treatment of malignant brain tumors: a reappraisal. Pediatr Transplant 1999;3(suppl 1):87-95.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.